Accelerating and de-risking late pre-clinical drug development with the Zebrafish Tumor Xenograph (ZTX®) Platform

Nearly 95% of oncology drug candidates fail during clinical development, primarily due to heterogeneous patient responses. Personalized pre-clinical testing is essential to improve translational success. Traditional mouse PDX or organoid models are limited by low engraftment rates, high cost, and long timelines. The Zebrafish Tumor Xenograph (ZTX®) model provides a rapid, cost-effective alternative, enabling individualized drug-response profiling within five days, at sensitivity and specificity comparable to mouse PDXs at a fraction of the cost.

This study aimed to evaluate the anti-tumor efficacy of novel drug candidates, alone or in combination with other oncological therapies, on xenographs generated from established cell lines, patient-derived cell lines, and primary clinical tumor samples using the ZTX® platform, demonstrating the benefit of using ZTX® models during late pre-clinical drug development.

Download the poster

Please enable JavaScript in your browser to complete this form.

Organisation Name Email

Name *

First

Last

Organisation *

Email *

Submit

We respect your privacy. Your data is kept safe and used only internally in accordance with our Privacy Policy.